Prot #R668-AD-1526: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients ≥12 to <18 Years of Age, with Moderate-to-Severe Atopic Dermatitis

Project: Research project

Project Details

StatusFinished
Effective start/end date8/21/178/21/20

Funding

  • ICON Clinical Research Limited (Prot #R668-AD-1526)
  • Regeneron Pharmaceuticals, Inc. (Prot #R668-AD-1526)